#United States #San Diego #Microneedle Technology #WCC Biomedical #WINMAP

Unveiling Microneedle Drug Delivery Innovation at NACDS

WCC Biomedical, a front-runner in the development of cutting-edge drug delivery systems, will take center stage at the upcoming NACDS Total Store Expo (TSE) scheduled for August 23-25 in San Diego, California. During this event, the company aims to showcase its proprietary WINMAP™ microarray patch (MAP) technology, which promises to revolutionize the way drugs and vaccines are administered.

The Total Store Expo is a significant gathering of decision-makers in the retail pharmacy sector, making it the perfect venue for WCC Biomedical to launch two groundbreaking products. After a successful introduction at BIO Asia in Taiwan, the company plans to demonstrate its innovative microneedle-based solutions, which include a homeopathic pain-relief patch and a herbal MACA patch — both leveraging the WINMAP technology. Attendees are invited to visit WCC at Booth #900 to witness firsthand the advantages of these microneedle patches.

WCC Biomedical's Innovation

WCC Biomedical's WINMAP™ platform represents a monumental leap forward in microneedle technology. According to Dr. Ta-Jo Liu, Chairman and CEO of WCC Biomedical, this platform offers an unparalleled combination of high-precision molding, accurate drug loading, and efficient mass production capabilities. The goal is to provide a needle-free, painless method to deliver active ingredients, addressing not only patient discomfort but also reducing the risk of infection associated with traditional injections.

The WINMAP™ system incorporates micrometer-scale needles crafted from medical-grade polymers, offering a painless skin delivery mechanism that prioritizes comfort and safety. This next-generation delivery system utilizes a novel approach that integrates penetration, dissolution, diffusion, and formulation, making it a more effective solution than conventional transdermal patches or topical creams.

Key Features of WINMAP™ Technology

• - Needle-Free, Pain-Free Delivery: This innovative approach completely removes the need for syringes, thus minimizing patient discomfort and mitigating infection risks.
• - Scalable Production: WCC Biomedical's automated production lines enable the creation of over 10 million MAPs per year, ensuring high consistency and yield.
• - Precision Loading and Coating (PLC): Customizable molding and precise dosing capabilities enhance the efficiency of drug delivery.
• - Advanced Formulation Databases: The Microneedles Material Database (MMDB) and Microneedles Formulation Database (MFDB) facilitate quick development processes that cater to varied release profiles.

A Leader in Drug Delivery Innovation

WCC Biomedical is recognized as a trailblazer in microneedle drug delivery systems, combining precise polymer engineering with advanced formulation science and scalable manufacturing methodologies. This combination allows them to create innovative MAPs aimed at improving healthcare, pharmaceutical services, and beauty care solutions. As part of their growth strategy, WCC is currently in a fundraising round targeting a minimum of $7 million to support the expansion of commercial production, with IPO plans in place for 2027.

Looking ahead to Q1 2026, WCC is gearing up to launch several new offerings while also targeting a listing on Taiwan's emerging market board. The company holds a portfolio of 14 international patents across markets including the US, EU, and Japan. Notably, WCC was recognized as a finalist in Taiwan’s Moderna mRNA Innovation Competition in 2024 and stands alone as the only Taiwanese company acknowledged by premier U.S. NGOs in the realm of health equity.

Commitment to Advancing Health Equity

WCC Biomedical's innovative MAPs not only enhance comfort for patients but also represent a viable alternative for regions with limited resources where conventional therapies might be unfeasible. As medical aid diminishes in the developing world, technologies like WINMAP™ could serve as vital breakthroughs in improving global health equity.

For further information about WCC Biomedical and their groundbreaking work in microneedle technology, please visit WCC Biomedical's Website.

Founded in 2014 and headquartered in the Hsinchu Science Park of Taiwan, WCC Biomedical is dedicated to transforming drug delivery methodologies, making the process painless, efficient, and equitable for all.